(Q44487783)

English

"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

7

object named as

Shinichi Oka

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

Atsuko Hachiya

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Saori Matsuoka-Aizawa

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Kiyoto Tsuchiya

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hiroyuki Gatanaga

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Satoshi Kimura

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Masashi Tatsumi

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 July 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Journal of Virological Methods

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

111

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

43-53

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Pharmacokinetic enhancement of protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Extent of human immunodeficiency virus type 1 drug resistance as a predictor of virological failure after genotype-guided treatment switch

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine (3TC) phosphorylation and drug interactions in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phenotypic testing predicts virological response in successive protease inhibitor-based regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: potential approach towards effective chemotherapy against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of rates of intracellular metabolism of zidovudine in human and primate peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The triple combination indinavir-zidovudine-lamivudine is highly synergistic

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A sensitive nonisotopic method for the determination of intracellular azidothymidine 5′-mono-, 5′-di-, and 5′-triphosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure

1 reference

https://api.crossref.org/works/10.1016%2FS0166-0934%2803%2900150-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0166-0934(03)00150-2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44487783&oldid=2025571460"